Health and fertility in world health organization group 2 anovulatory women

D. T. Baird, A. Balen, H. F. Escobar-Morreale, J. L H Evers, B. C J M Fauser, S. Franks, A. Glasier, R. Homburg, C. La Vecchia, P. G. Crosignani, P. Devroey, K. Diedrich, L. Fraser, L. Gianaroli, I. Liebaers, A. Sunde, J. S. Tapanainen, B. Tarlatzis, A. Van Steirteghem, A. Veiga

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background: Disruption of ovulation occurs in different types of clinical infertility. The World Health Organization (WHO) has provided a classification of ovulation disorders. This review focuses on WHO group 2 anovulation. Methods: Searches were performed in Medline/PubMed and EMBASE. Each subject summary was presented to the European Society of Human Reproduction and Embryology (ESHRE) Workshop Group, where omissions or disagreements were resolved by discussion. Results: Disorders resulting in ovulatory disturbances are a relatively common cause of infertility. They occur most frequently in the context of WHO group 2 anovulation as reflected, for example, in the polycystic ovary syndrome (PCOS). The aetiology of PCOS remains unclear but evidence exists for a multifactorial origin with a genetic predisposition. Women with PCOS show an increased time to pregnancy but their eventual family size is not necessarily reduced. Also their frequency of miscarriage does not appear increased. Clomiphene citrate is still the first-line treatment in subfertile anovulatory patients with PCOS, with gonadotrophins and laparoscopic ovarian surgery as second-line options. Aromatase inhibitors show promising results. Conclusions: Long-term health risks in patients with WHO group 2 anovulation demand their general health be monitored, even after their reproductive needs have been fulfilled. Metabolic and cardiovascular risk prevention in women with PCOS should start as early as possible. It is not easy to analyse the possible role of PCOS, independent of obesity, metabolic syndrome, insulin resistance and diabetes, on long-term health.

Original languageEnglish
Article numberdms019
Pages (from-to)586-599
Number of pages14
JournalHuman Reproduction Update
Volume18
Issue number5
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Polycystic Ovary Syndrome
Fertility
Anovulation
Health
Ovulation
Infertility
Time-to-Pregnancy
Clomiphene
Aromatase Inhibitors
Spontaneous Abortion
Genetic Predisposition to Disease
Gonadotropins
PubMed
Laparoscopy
Insulin Resistance
Obesity
Education

Keywords

  • Endocrine control of reproduction
  • Ovarian insufficiency
  • Polycystic ovaries
  • Polycystic ovary syndrome
  • WHO group 2 anovulation

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Baird, D. T., Balen, A., Escobar-Morreale, H. F., Evers, J. L. H., Fauser, B. C. J. M., Franks, S., ... Veiga, A. (2012). Health and fertility in world health organization group 2 anovulatory women. Human Reproduction Update, 18(5), 586-599. [dms019]. https://doi.org/10.1093/humupd/dms019

Health and fertility in world health organization group 2 anovulatory women. / Baird, D. T.; Balen, A.; Escobar-Morreale, H. F.; Evers, J. L H; Fauser, B. C J M; Franks, S.; Glasier, A.; Homburg, R.; La Vecchia, C.; Crosignani, P. G.; Devroey, P.; Diedrich, K.; Fraser, L.; Gianaroli, L.; Liebaers, I.; Sunde, A.; Tapanainen, J. S.; Tarlatzis, B.; Van Steirteghem, A.; Veiga, A.

In: Human Reproduction Update, Vol. 18, No. 5, dms019, 09.2012, p. 586-599.

Research output: Contribution to journalArticle

Baird, DT, Balen, A, Escobar-Morreale, HF, Evers, JLH, Fauser, BCJM, Franks, S, Glasier, A, Homburg, R, La Vecchia, C, Crosignani, PG, Devroey, P, Diedrich, K, Fraser, L, Gianaroli, L, Liebaers, I, Sunde, A, Tapanainen, JS, Tarlatzis, B, Van Steirteghem, A & Veiga, A 2012, 'Health and fertility in world health organization group 2 anovulatory women', Human Reproduction Update, vol. 18, no. 5, dms019, pp. 586-599. https://doi.org/10.1093/humupd/dms019
Baird DT, Balen A, Escobar-Morreale HF, Evers JLH, Fauser BCJM, Franks S et al. Health and fertility in world health organization group 2 anovulatory women. Human Reproduction Update. 2012 Sep;18(5):586-599. dms019. https://doi.org/10.1093/humupd/dms019
Baird, D. T. ; Balen, A. ; Escobar-Morreale, H. F. ; Evers, J. L H ; Fauser, B. C J M ; Franks, S. ; Glasier, A. ; Homburg, R. ; La Vecchia, C. ; Crosignani, P. G. ; Devroey, P. ; Diedrich, K. ; Fraser, L. ; Gianaroli, L. ; Liebaers, I. ; Sunde, A. ; Tapanainen, J. S. ; Tarlatzis, B. ; Van Steirteghem, A. ; Veiga, A. / Health and fertility in world health organization group 2 anovulatory women. In: Human Reproduction Update. 2012 ; Vol. 18, No. 5. pp. 586-599.
@article{afce26f656cb48678d6034a24fd82297,
title = "Health and fertility in world health organization group 2 anovulatory women",
abstract = "Background: Disruption of ovulation occurs in different types of clinical infertility. The World Health Organization (WHO) has provided a classification of ovulation disorders. This review focuses on WHO group 2 anovulation. Methods: Searches were performed in Medline/PubMed and EMBASE. Each subject summary was presented to the European Society of Human Reproduction and Embryology (ESHRE) Workshop Group, where omissions or disagreements were resolved by discussion. Results: Disorders resulting in ovulatory disturbances are a relatively common cause of infertility. They occur most frequently in the context of WHO group 2 anovulation as reflected, for example, in the polycystic ovary syndrome (PCOS). The aetiology of PCOS remains unclear but evidence exists for a multifactorial origin with a genetic predisposition. Women with PCOS show an increased time to pregnancy but their eventual family size is not necessarily reduced. Also their frequency of miscarriage does not appear increased. Clomiphene citrate is still the first-line treatment in subfertile anovulatory patients with PCOS, with gonadotrophins and laparoscopic ovarian surgery as second-line options. Aromatase inhibitors show promising results. Conclusions: Long-term health risks in patients with WHO group 2 anovulation demand their general health be monitored, even after their reproductive needs have been fulfilled. Metabolic and cardiovascular risk prevention in women with PCOS should start as early as possible. It is not easy to analyse the possible role of PCOS, independent of obesity, metabolic syndrome, insulin resistance and diabetes, on long-term health.",
keywords = "Endocrine control of reproduction, Ovarian insufficiency, Polycystic ovaries, Polycystic ovary syndrome, WHO group 2 anovulation",
author = "Baird, {D. T.} and A. Balen and Escobar-Morreale, {H. F.} and Evers, {J. L H} and Fauser, {B. C J M} and S. Franks and A. Glasier and R. Homburg and {La Vecchia}, C. and Crosignani, {P. G.} and P. Devroey and K. Diedrich and L. Fraser and L. Gianaroli and I. Liebaers and A. Sunde and Tapanainen, {J. S.} and B. Tarlatzis and {Van Steirteghem}, A. and A. Veiga",
year = "2012",
month = "9",
doi = "10.1093/humupd/dms019",
language = "English",
volume = "18",
pages = "586--599",
journal = "Human Reproduction Update",
issn = "1355-4786",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Health and fertility in world health organization group 2 anovulatory women

AU - Baird, D. T.

AU - Balen, A.

AU - Escobar-Morreale, H. F.

AU - Evers, J. L H

AU - Fauser, B. C J M

AU - Franks, S.

AU - Glasier, A.

AU - Homburg, R.

AU - La Vecchia, C.

AU - Crosignani, P. G.

AU - Devroey, P.

AU - Diedrich, K.

AU - Fraser, L.

AU - Gianaroli, L.

AU - Liebaers, I.

AU - Sunde, A.

AU - Tapanainen, J. S.

AU - Tarlatzis, B.

AU - Van Steirteghem, A.

AU - Veiga, A.

PY - 2012/9

Y1 - 2012/9

N2 - Background: Disruption of ovulation occurs in different types of clinical infertility. The World Health Organization (WHO) has provided a classification of ovulation disorders. This review focuses on WHO group 2 anovulation. Methods: Searches were performed in Medline/PubMed and EMBASE. Each subject summary was presented to the European Society of Human Reproduction and Embryology (ESHRE) Workshop Group, where omissions or disagreements were resolved by discussion. Results: Disorders resulting in ovulatory disturbances are a relatively common cause of infertility. They occur most frequently in the context of WHO group 2 anovulation as reflected, for example, in the polycystic ovary syndrome (PCOS). The aetiology of PCOS remains unclear but evidence exists for a multifactorial origin with a genetic predisposition. Women with PCOS show an increased time to pregnancy but their eventual family size is not necessarily reduced. Also their frequency of miscarriage does not appear increased. Clomiphene citrate is still the first-line treatment in subfertile anovulatory patients with PCOS, with gonadotrophins and laparoscopic ovarian surgery as second-line options. Aromatase inhibitors show promising results. Conclusions: Long-term health risks in patients with WHO group 2 anovulation demand their general health be monitored, even after their reproductive needs have been fulfilled. Metabolic and cardiovascular risk prevention in women with PCOS should start as early as possible. It is not easy to analyse the possible role of PCOS, independent of obesity, metabolic syndrome, insulin resistance and diabetes, on long-term health.

AB - Background: Disruption of ovulation occurs in different types of clinical infertility. The World Health Organization (WHO) has provided a classification of ovulation disorders. This review focuses on WHO group 2 anovulation. Methods: Searches were performed in Medline/PubMed and EMBASE. Each subject summary was presented to the European Society of Human Reproduction and Embryology (ESHRE) Workshop Group, where omissions or disagreements were resolved by discussion. Results: Disorders resulting in ovulatory disturbances are a relatively common cause of infertility. They occur most frequently in the context of WHO group 2 anovulation as reflected, for example, in the polycystic ovary syndrome (PCOS). The aetiology of PCOS remains unclear but evidence exists for a multifactorial origin with a genetic predisposition. Women with PCOS show an increased time to pregnancy but their eventual family size is not necessarily reduced. Also their frequency of miscarriage does not appear increased. Clomiphene citrate is still the first-line treatment in subfertile anovulatory patients with PCOS, with gonadotrophins and laparoscopic ovarian surgery as second-line options. Aromatase inhibitors show promising results. Conclusions: Long-term health risks in patients with WHO group 2 anovulation demand their general health be monitored, even after their reproductive needs have been fulfilled. Metabolic and cardiovascular risk prevention in women with PCOS should start as early as possible. It is not easy to analyse the possible role of PCOS, independent of obesity, metabolic syndrome, insulin resistance and diabetes, on long-term health.

KW - Endocrine control of reproduction

KW - Ovarian insufficiency

KW - Polycystic ovaries

KW - Polycystic ovary syndrome

KW - WHO group 2 anovulation

UR - http://www.scopus.com/inward/record.url?scp=84865097268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865097268&partnerID=8YFLogxK

U2 - 10.1093/humupd/dms019

DO - 10.1093/humupd/dms019

M3 - Article

C2 - 22611175

AN - SCOPUS:84865097268

VL - 18

SP - 586

EP - 599

JO - Human Reproduction Update

JF - Human Reproduction Update

SN - 1355-4786

IS - 5

M1 - dms019

ER -